Congressional Biomedical Research Caucus

Congressional Biomedical Research Caucus
Name	Congressional Biomedical Research Caucus
Formation	2003
Founder	Rep. Vernon J. Ehlers
Type	Congressional caucus
Headquarters	Washington, D.C.
Leaders	House and Senate members

Congressional Biomedical Research Caucus is a congressional caucus in the United States House of Representatives focused on biomedical research policy, advocacy, and funding. It convenes members of Congress, scientific organizations, medical institutions, and advocacy groups to discuss funding priorities for agencies such as the National Institutes of Health, the Food and Drug Administration, and the Centers for Disease Control and Prevention. The caucus links legislative priorities with stakeholders including academic medical centers, philanthropic organizations, and private-sector research firms.

History

The caucus was founded in 2003 by Representative Vern Ehlers alongside collaborators from entities like the American Association for the Advancement of Science, the Federation of American Societies for Experimental Biology, and the Association of American Medical Colleges. Early meetings featured speakers from NIH Director Elias A. Zerhouni era delegations, representatives of the Howard Hughes Medical Institute, and policy analysts from the Kaiser Family Foundation and the Congressional Budget Office. Over time, the caucus intersected with major legislative moments including deliberations on the 21st Century Cures Act, budget negotiations involving the Appropriations Committee (United States House of Representatives), and oversight inquiries touching the Food and Drug Administration Modernization Act discussions. Prominent participants have included members associated with committees like the House Energy and Commerce Committee, the House Committee on Science, Space, and Technology, and senators aligned with the Senate Health, Education, Labor and Pensions Committee.

Mission and Objectives

The caucus advances objectives such as advocating for sustained funding for institutions like the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Institute of Mental Health. It promotes translational science interactions among stakeholders including Johns Hopkins University School of Medicine, Mayo Clinic, Massachusetts Institute of Technology, and industry partners like Pfizer, Johnson & Johnson, and Amgen. The caucus emphasizes policies to streamline regulatory pathways involving the Food and Drug Administration and to foster public-private partnerships exemplified by collaborations with the Bill & Melinda Gates Foundation and the Wellcome Trust. It seeks to align congressional appropriations with recommendations from advisory bodies such as the National Academy of Medicine and the President's Council of Advisors on Science and Technology.

Membership and Leadership

Membership typically comprises members of the United States House of Representatives with interest in health policy, including lawmakers from districts with major research universities like Stanford University, University of California, San Francisco, and University of Pennsylvania. Leadership has included representatives who serve, or have served, on panels such as the House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies and the House Committee on Ways and Means. The caucus often invites participation from senators, mayors from cities like Boston, Baltimore, and Houston, and leaders of institutions like the American Cancer Society and the Alzheimer's Association. External advisory rosters have included executives from the American Heart Association, chief executives of biotechnology firms such as Genentech, and directors from the Centers for Medicare & Medicaid Services policy divisions.

Activities and Initiatives

Activities include briefings, roundtables, and hearings with stakeholders including investigators from Harvard Medical School, researchers from Cold Spring Harbor Laboratory, and executives from Biogen. Initiatives have centered on accelerating drug development pathways, supporting workforce development programs tied to the National Science Foundation, and championing disease-specific research efforts for conditions represented by advocacy groups such as Susan G. Komen for the Cure, Michael J. Fox Foundation for Parkinson's Research, and the Cystic Fibrosis Foundation. The caucus organizes events with participation from agencies like the Office of Management and Budget, charitable funders like the Robert Wood Johnson Foundation, and trade associations including BIO (trade association). It has also engaged with global health partners such as World Health Organization delegations and researchers affiliated with Institut Pasteur.

Funding and Influence

While the caucus itself is not a grant-making body, it exerts influence on appropriations and policy debates that affect funding for entities like the National Institutes of Health and programs within the Defense Advanced Research Projects Agency. Its convening power draws contributions and testimony from philanthropies such as the Howard Hughes Medical Institute and corporate research arms including Merck & Co. and Novartis. The caucus has been cited in policy discussions around budget caps set by Congressional Budget Act of 1974 implementations and in advocacy campaigns coordinated by coalitions like the Research!America and the Campaign for Medical Research. Through hearings and letters, caucus members have influenced appropriation levels overseen by the House Appropriations Committee and the Senate Appropriations Committee.

Criticism and Controversies

Critics have argued that the caucus can reflect tensions between academia, industry, and public-interest advocates, citing potential conflicts involving pharmaceutical lobbying by firms such as Eli Lilly and Company and GlaxoSmithKline. Concerns have been raised about revolving-door dynamics involving former staff moving between congressional offices and think tanks like the Brookings Institution or firms like McKinsey & Company. Debates have occurred over research priorities, including prioritization of rare disease programs championed by groups such as the EveryLife Foundation for Rare Diseases versus population health investments advocated by public health scholars at Columbia University Mailman School of Public Health. Transparency advocates referencing organizations like OpenSecrets and reporters from outlets such as The New York Times and The Washington Post have scrutinized donor influence and the role of industry-funded studies in shaping caucus agendas.

Category:United States congressional caucuses